


# Niger

African Region





## I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	20,700,000	100	Plasmodium species: <i>P. falciparum</i> (95%), <i>P. vivax</i> (0%)
Low transmission (0-1 cases per 1000 population)	-	-	Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i> , <i>An. arabiensis</i>
Malaria-free (0 cases)	-	-	Reported confirmed cases (health facility): 4,148,167 Estimated cases: 7,830,000 [3,760,000–13,150,000]
Total	20,670,000		Confirmed cases at community level: 109,943 Reported deaths: 2,226 Estimated deaths: 17,800 [13,930–21,680]



## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2005	First-line treatment of unconfirmed malaria	AL	2005					
	ITNs/ LLINs distributed to all age groups	Yes	2005	First-line treatment of <i>P. falciparum</i>	AL	2005					
IRS	IRS is recommended	Yes	2003	Treatment failure of <i>P. falciparum</i>	QN	2005					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS; QN	2005					
Larval control	Use of larval control recommended	Yes	2010	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2005	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	-	-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	1998	Type of RDT used	-	<i>P. f</i> only					
	Malaria diagnosis is free of charge in the public sector	Yes	2000								
Treatment	ACT is free of charge for all ages in public sector	No	2008	<b>Therapeutic efficacy tests (clinical and parasitological failure, %)</b>							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	2007	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2011-2011	5.3	5.3	5.3	28 days	1	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	<b>Insecticide resistance tests (mosquito mortality, %)</b>							
	G6PD test is a requirement before treatment with primaquine	-	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	Directly observed treatment with primaquine is undertaken	No	-	Organochlorines	2013-2013	0	0	0.1	2	<i>An. coluzzii</i>	
	System for monitoring adverse reactions to antimalarials exists	Yes	-	Organophosphates	2013-2013	1	1	1	3	<i>An. coluzzii</i>	
Surveillance	ACD for case investigation (reactive)	No	-	Carbamates	2013-2013	1	1	1	3	<i>An. coluzzii</i>	
	ACD of febrile cases at community level (pro-active)	No	-	Pyrethroids	2013-2013	0	0.3	0.8	4	<i>An. coluzzii</i>	
	Mass screening is undertaken	No	-								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
	Case reporting from private sector is mandatory	Yes	-								



## III. Financing




## IV. Coverage



## V. Impact



## Confirmed malaria cases per 1000 and ABER



## Malaria admissions and deaths (per 100 000)

